eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today
Key Highlights
- ➤$3.05 million Q3 operating expenses, up from $2.52 million year over year
- ➤$2.24 million Q3 net loss; nine-month net loss reached $7.49 million
- ➤$3.26 million cash expected to support operations through beginning of 2027
- ➤Curia selected for commercial-scale NCT manufacturing, targeting larger-scale production in 2027
- ➤SAPPHIRE and AMETHYST supplement candidates advanced through proof of concept
Expert Statements
Michael Heltzen, CEO of eXoZymes
“We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart.”
LOS ANGELES, CA / ACCESS Newswire / November 19, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar at 5:00 PM Eastern Time to discuss results for the third quarter ended September 30, 2026, and provide an update on recent business developments.
Michael Heltzen, CEO of eXoZymes, states, "We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart."
Get started
Create a free account to read the full story.
